Rosiglitazone prevents hepatic fibrosis?

A research article has been published on May 14, 2008 in the World Journal of Gastroenterology, which describes that hepatic Schitosomiasis is one of the most prevalent forms of chronic liver diseases in the world. However, few drugs or treatment modalities are available for liver fibrosis due to infection with Schitosoma. Activation of PPAR gamma plays a leading role in adipocyte differentiation and glucose metabolism. Rosiglitazone and its analogues are generally used as antidiabetic drugs in clinical practice. However, as a therapeutic agent, rosiglitazone can also prevent hepatic fibrosis.

PPARgamma is mainly expressed in human HSC and contributes to liver fibrogenesis. PPAR gamma ligand may herald a new therapeutic approach to liver fibrosis following infection with Schistosoma japonicum. Whether PPAR gamma is a novel modulator for liver fibrosis remains controversial. Further research is needed to explain the mechanism by which PPAR gamma ligand prevents hepatic fibrosis.